Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced.

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...

Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

Diagnosis also required -- and still does -- the presence of at least 10% infiltration of clonal plasma cells on bone marrow examination or a biopsy-proven bony or extramedullary plasmacytoma ...

Fresenius Kabi’s fifth and sixth biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) have launched in the ...

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...